首页TTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
昨日收盘价
$3.72
当日价格范围
$3.62 - $3.76
年度波幅
$3.03 - $14.80
市值
343.75万 USD
平均交易量
2.81万
市盈率
-
股息率
-
主要交易所
NASDAQ
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 66.60万 | -53.88% |
净收入 | -79.00万 | 59.90% |
净利润率 | — | — |
每股收益 | — | — |
息税折旧摊销前利润 | -66.60万 | 65.46% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 283.10万 | -58.12% |
总资产 | 292.30万 | -63.85% |
负债总额 | 48.30万 | -66.55% |
权益总额 | 244.00万 | — |
发行在外的股份 | 91.42万 | — |
市净率 | 1.39 | — |
资产回报率 | -51.03% | — |
资本回报率 | -58.72% | — |
现金流
现金净变动
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
净收入 | -79.00万 | 59.90% |
来自运营的现金 | -50.60万 | 77.47% |
投资现金 | — | — |
融资现金 | -6.20万 | -115.27% |
现金净变动 | -56.80万 | 57.49% |
自由现金流 | -19.32万 | 80.89% |
简介
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
成立时间
1991
员工数量
4
